Skip to main content
Retour
DSGN logo

Design Therapeutics, Inc.

Qualité des données : 100%
DSGN
NASDAQ Healthcare Biotechnology
10,31 €
▲ 0,14 € (1,38%)
Cap. Boursière : 635,84M
Fourchette du Jour
9,90 € 10,36 €
Fourchette 52 Semaines
2,60 € 11,23 €
Volume
172 106
Moyenne 50J / 200J
10,15 € / 7,17 €
Clôture Précédente
10,17 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -9,1 0,3
P/B 3,0 2,9
ROE % -30,7 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
15,67 € +52.0%
Low: 14,00 € High: 18,00 €
BPA Prévisionnel
-1,36 €
CA Est.
120 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 -0,41 €
-0,41 € – -0,41 €
220 M 2
FY2029 -1,61 €
-1,61 € – -1,61 €
69 M 2
FY2028 -2,01 €
-2,38 € – -1,61 €
8,5 M 4

Points Clés

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -54,55M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-30,70%
ROIC-27,96%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,00
Current Ratio17,14
Interest Coverage0,00

Valorisation

P/E Ratio
-9,11
P/B Ratio2,99
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -69,79M
ROE -30,70% ROA -30,85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -54,55M
ROIC -27,96% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 17,14
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -9,11 P/B Ratio 2,99
P/S Ratio N/A PEG Ratio -0,20
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 635,84M Enterprise Value 619,63M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -69,79M -49,59M -66,86M -63,31M -35,53M
EPS (Diluted) -1,22 -0,88 -1,19 -1,14 -0,77
Gross Profit -622 000,0 -596 000,0 -537 000,0 -466 000,0 0,0
Operating Income -79,47M -62,38M -78,19M -67,59M -35,83M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 226,20M 252,09M 289,64M 341,14M 390,56M
Total Liabilities 13,70M 10,00M 11,96M 13,83M 8,43M
Shareholders' Equity 212,50M 242,10M 277,69M 327,31M 382,13M
Total Debt 645 000,0 2,33M 3,05M 3,69M 3,63M
Cash & Equivalents 16,86M 22,56M 21,20M 26,50M 298,57M
Current Assets 223,78M 248,04M 284,58M 335,12M 385,44M
Current Liabilities 13,06M 8,46M 9,62M 10,78M 5,28M